Impact of age at diagnosis of de novo metastatic prostate cancer on survival.
age at onset
metastases
prostate cancer
survival
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
09
07
2019
revised:
26
09
2019
accepted:
27
10
2019
pubmed:
27
11
2019
medline:
21
10
2020
entrez:
27
11
2019
Statut:
ppublish
Résumé
An older age at the diagnosis of prostate cancer has been linked to worse prostate cancer-specific survival (PCSS). However, these studies were conducted before the approval of many life-prolonging drugs. This study was aimed at describing outcomes in a contemporary cohort of men diagnosed with de novo metastatic prostate cancer (mPCa) and assessing associations with the age at diagnosis while controlling for known prognostic factors. The Surveillance, Epidemiology, and End Results registry was used to identify men diagnosed with mPCa from 2004 to 2014. Men were classified by 4 age groups: ≤54, 55 to 64, 65 to 74, and ≥75 years. The median overall survival, PCSS, and restricted mean survival times for any-cause mortality and prostate cancer-specific mortality (PCSM) were calculated. Multivariable and subdistribution hazard ratios for PCSM according to age group and with controlling for race, marital status, and income were estimated. Compared with men aged ≤54 years, men aged ≥75 years experienced a mean PCSS at 5 years that was 6.7 months shorter (95% confidence interval [CI], 5.5-7.8 months). In multivariable analyses, men aged ≥75 years had a 49% increase in the rate of PCSM in comparison with those aged ≤54 years (95% CI, 1.39-1.60). The subdistribution hazard ratio for PCSM between these groups was 1.41 (95% CI, 1.32-1.50). Age was found to be an independent predictor of shorter PCSS in men diagnosed with de novo mPCa even in an era with more effective therapies. Further work is needed to determine the reason for poor outcomes in older men with mPCa.
Sections du résumé
BACKGROUND
An older age at the diagnosis of prostate cancer has been linked to worse prostate cancer-specific survival (PCSS). However, these studies were conducted before the approval of many life-prolonging drugs. This study was aimed at describing outcomes in a contemporary cohort of men diagnosed with de novo metastatic prostate cancer (mPCa) and assessing associations with the age at diagnosis while controlling for known prognostic factors.
METHODS
The Surveillance, Epidemiology, and End Results registry was used to identify men diagnosed with mPCa from 2004 to 2014. Men were classified by 4 age groups: ≤54, 55 to 64, 65 to 74, and ≥75 years. The median overall survival, PCSS, and restricted mean survival times for any-cause mortality and prostate cancer-specific mortality (PCSM) were calculated. Multivariable and subdistribution hazard ratios for PCSM according to age group and with controlling for race, marital status, and income were estimated.
RESULTS
Compared with men aged ≤54 years, men aged ≥75 years experienced a mean PCSS at 5 years that was 6.7 months shorter (95% confidence interval [CI], 5.5-7.8 months). In multivariable analyses, men aged ≥75 years had a 49% increase in the rate of PCSM in comparison with those aged ≤54 years (95% CI, 1.39-1.60). The subdistribution hazard ratio for PCSM between these groups was 1.41 (95% CI, 1.32-1.50).
CONCLUSIONS
Age was found to be an independent predictor of shorter PCSS in men diagnosed with de novo mPCa even in an era with more effective therapies. Further work is needed to determine the reason for poor outcomes in older men with mPCa.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
986-993Informations de copyright
© 2019 American Cancer Society.
Références
National Cancer Institute. Cancer Stat Facts: Prostate Cancer. Accessed September 25, 2018. http://seer.cancer.gov/statfacts/html/prost.html
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
Negoita S, Feuer EJ, Mariotto A, et al. Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124:2801-2814.
Wu JN, Fish KM, Evans CP, Devere White RW, Dall’Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818-823.
Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256-262.
Finianos A, Gupta K, Clark B, Simmens SJ, Aragon-Ching JB. Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease. Clin Genitourin Cancer. 2018;16:85-89.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737-746.
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352-360.
Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36:1080-1087.
Iacovelli R, Ciccarese C, Mosillo C, et al. Comparison between prognostic classifications in de novo metastatic hormone sensitive prostate cancer. Target Oncol. 2018;13:649-655.
Buelens S, Poelaert F, Dhondt B, et al. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol. 2018;36:158.e13-158.e20.
Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118:3062-3070.
Humphreys MR, Fernandes KA, Sridhar SS. Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC). J Cancer. 2013;4:304-314.
MacKintosh FR, Sprenkle PC, Walter LC, et al. Age and prostate-specific antigen level prior to diagnosis predict risk of death from prostate cancer. Front Oncol. 2016;6:157.
DiBlasio CJ, Malcolm JB, Hammett J, et al. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience. BJU Int. 2009;104:1208-1214.
Miyoshi Y, Noguchi K, Yanagisawa M, et al. Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer. BMC Cancer. 2015;15:338.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
A’Hern RP. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials? J Clin Oncol. 2016;34:3474-3476.
Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30:2409-2421.
Groenwold RH, White IR, Donders AR, Carpenter JR, Altman DG, Moons KG. Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis. CMAJ. 2012;184:1265-1269.
Miettinen OS. Theoretical Epidemiology: Principles of Occurrence Research. John Wiley & Sons Inc; 1985.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
Trinquart L, Bill-Axelson A, Rider JR. Restricted mean survival times to improve communication of evidence from cancer randomized trials and observational studies. Eur Urol. 2019;76:137-139.
San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int. 2014;114:229-235.
Chan YX, Knuiman MW, Divitini ML, Handelsman DJ, Beilby JP, Yeap BB. Lower circulating androgens are associated with overall cancer risk and prostate cancer risk in men aged 25-84 years from the Busselton Health Study. Horm Cancer. 2018;9:391-398.
Pichon A, Neuzillet Y, Botto H, et al. Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading. Prostate Cancer Prostatic Dis. 2015;18:382-387.
Muralidhar V, Ziehr DR, Mahal BA, et al. Association between older age and increasing Gleason score. Clin Genitourin Cancer. 2015;13:525-530.e3.
Maines F, Caffo O, De Giorgi U, et al. Safety and clinical outcomes of abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the Italian Compassionate Use Named Patient Programme. Clin Genitourin Cancer. 2016;14:48-55.
Mulders PF, Molina A, Marberger M, et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol. 2014;65:875-883.
Maia MC, Pereira AAL, Lage LV, et al. Efficacy and safety of docetaxel in elderly patients with metastatic castration-resistant prostate cancer. J Glob Oncol. 2018;4:1-9.
Graff JN, Beer TM. Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs Aging. 2014;31:873-882.
Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15:e404-e414.
Kilari D, Dale W, Mohile SG. How we treat early systemic prostate cancer in older men. J Geriatr Oncol. 2014;5:337-342.
Handforth C, Burkinshaw R, Freeman J, et al. Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer. Support Care Cancer. 2019;27:1755-1763.